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for registration trials may be identified. This review pro-
vides a systematic survey of the applications submitted to 
the United States Food and Drug Administration (FDA) 
for oncology indications, from 2010 through early 2015, 
and summarizes the dose selection rationale for registra-
tional trials, the relationship of the MTD to outcomes of the 
final label dose, the postmarketing requirements or com-
mitments related to dose optimization activities, the role 
of biomarkers, and typical exposure–response modeling 
methods.
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Introduction: the changing environment for dose 
selection and optimization in oncology
A previous review of new drug applications submitted to 
the United States Food and Drug Administration (hereaf-
ter referred to as “FDA”) during 2000–2012 for different 
indications showed that drugs commonly failed to gain 
approval if they lacked a definitive optimal dose which 
maximizes efficacy and minimizes safety risks [1]. Parallel 
to this analysis, two recent publications on oncology drug 
development reviewed the challenges faced in selecting and 
optimizing doses for registration of clinical trials, and out-
lined potential strategies and data elements [2, 3]. With the 
continuing evolution of cancer drug development, a critical 
emerging issue is how to optimally dose agents for maxi-
mal efficacy, minimal toxicity, and optimal clinical applica-
tion and cost-benefit [2–4].
Historically, dose selection of cytotoxic cancer chemo-
therapies considered the value of large and frequent doses 
Abstract  The maximally tolerated dose (MTD) of cyto-
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it was believed that dose and therapeutic effect are intrin-
sically linked and that the MTD would provide greatest 
therapeutic value. With molecularly targeted agents, the 
premise of preventing toxicity to normal tissues while mod-
ulating tumor growth provides a potential for an increased 
therapeutic window. Results from these targeted agents 
suggest we are entering an era of chronic cancer manage-
ment, which will require design of regimens with long-term 
tolerability. A corresponding switch from MTD-based (tox-
icity-driven) dosing strategies to alternative paradigms is 
also expected. The challenge with these targeted agents is 
to fully understand the complex relationship between phar-
macokinetics, pharmacodynamics, and safety and efficacy 
in early-stage trials, so that the optimal dose and schedule 
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which would provide significant tumor cell killing to 
achieve complete responses (fractional killing) and prevent 
development of resistance in residual clinically undetect-
able disease [5, 6]. Dose selection was usually done after 
treating small cohorts of patients, typically enrolled in 
Phase 1 dose escalation trials, who received a pre-specified 
dose in a cohort which resulted in clinically limiting toxic-
ity (dose limiting toxicity; DLT). The “maximum tolerated 
dose” (MTD), a lower dose with more acceptable levels of 
toxicity, was then defined in a subsequent cohort. Thera-
peutic effect and tolerability were believed to be intrinsi-
cally linked, and the great risk–benefit considerations for 
cancers commonly dictated MTD selection for use in Phase 
2 and registration trials.
Molecularly targeted agents hold promise to spare 
normal tissues from toxicity while acting upon specific 
receptors or factors that are critical to promote tumor sur-
vival and growth. A continuing increase in the number of 
reports of clinical success with these agents illustrate the 
potentially favorable therapeutic window for treatment 
with molecular targeted agents. These success stories sug-
gest that we are entering an era where cancer is a disease 
to be managed chronically, making long-term tolerability 
of drugs and patient adherence increasingly important. As 
the transition from broadly cytotoxic to targeted therapies 
continues, there will be a corresponding switch from MTD-
based dosing to an alternative paradigm that better resem-
bles treatment of other chronic (non-oncologic) illnesses. 
Others have previously reviewed emerging concepts and 
strategies for determining the “optimal biologic dose” in 
an era of molecularly targeted and hormonal agents [2, 
3]. These reviews highlight the current challenge we face 
in fully understanding the complex relationships between 
pharmacokinetics, pharmacodynamics, safety, and efficacy 
in early-stage trials, where we aim to define the optimal 
dose for registration trials for oncology drug development.
Recent reviews have proposed that certain clinical trial 
design strategies and necessary data elements are required 
to enable identification of the optimal dose across all 
phases of clinical development. These elements include 
trial design features such as adaptive designs or rand-
omized dose explorations, coupled with adequate assess-
ment of pharmacokinetics and pharmacodynamics (i.e., 
biomarker response and clinical effect) in early clinical tri-
als, to assess relationships between drug exposure, target 
effect, and acute toxicity [2, 3]. In later phases of devel-
opment, it is also important to study the relationship of 
drug exposure to long-term clinical outcomes (both safety 
and efficacy) in the target patient population, where sparse 
pharmacokinetic sampling in registration trials would pro-
vide valuable insights on the optimal dose. Another impor-
tant attribute of these strategies is the study of patient char-
acteristics that determine pharmacokinetic variability, such 
as demographics (i.e., body weight, age, sex, etc.), physio-
logic factors (e.g., organ function), pathophysiological con-
ditions related to tumor/disease status, pharmacogenomics, 
co-medications, and others, which allow for further dose 
optimization for specific patient populations.
A previous review presented seven examples of recently 
approved oncology products to demonstrate that alternative 
doses are being evaluated in postmarketing trials, indicating 
that the label dose may not be the optimal dose [3]. To extend 
the knowledge of dose selection and optimization during clin-
ical development, we conducted a comprehensive survey of 
the label dose for New Molecular Entity (NME) applications 
for oncology drugs approved by the FDA from 2010 through 
the first quarter of 2015. This relatively narrow time frame 
was arbitrarily selected on our belief that exposure–response 
analyses may have been more consistently applied in the 
recent years of the drug review and approval process.
The key objectives of this survey are to systematically:
1. Evaluate the frequency of dose optimization-related post-
marketing requirements (PMR)/postmarketing commit-
ments (PMC);
2. Assess the outcomes for use for the MTD as the rec-
ommended dose for registration trials and the outcome 
of this dose selection strategy;
3. Summarize the use of upwards dose titration as a strat-
egy of dose optimization;
4. Provide representative examples of biomarkers as a 
guide to dose selection/justification,
5. Present an overview of the pharmacometric methods of 
exposure–response (E–R) analysis in NME applications.
Data sources
 This survey included NME New Drug Applications (NDA) 
or Biologics License Applications (BLA) for oncology 
indications that were approved by the FDA between 2010 
and through the first quarter of 2015. The information 
reviewed includes the “clinical pharmacology and biop-
harmaceutics review” documents publicly available from 
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/. 
The primary focus was on the exposure–response (E–R) 
summary, relating to the following question by the FDA 
reviewer: “is the dose and dosing regimen selected by the 
applicant consistent with the known relationship between 
dose–concentration–response?”. Label and approval let-
ters were reviewed to summarize the current label dose and 
the PMRs/PMCs [7] related to the label dose justification 
or optimization. Selected publications related to label dose 
justification for these drugs were also reviewed. The term 
“dose justification” is used to reflect the fact that the pro-
posed label dose in the application is supported by clinical 
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data based on FDA review, while “dose optimization” 
means that the sponsor was asked to consider post-approval 
activities such as PMR or PMC to identify any alternative 
dose which confers a better risk–benefit profile.
PMR and PMC refer to studies and clinical trials that 
sponsors conduct after FDA approval, to gather additional 
information about a product’s safety, efficacy, or optimal 
use. Further definition of PMRs includes studies and clini-
cal trials that sponsors are required to conduct under one or 
more statutes or regulations. PMCs are studies or clinical 
trials that a sponsor has agreed to conduct, but that are not 
required by a statute or regulation [7, 8].
Dose optimization‑related PMR/PMC for an 
oncology NME are common
During the survey period, the FDA approved 41 NME appli-
cations through the NDA or BLA review processes for can-
cer indications. Figure 1 provides chronological depiction of 
these drugs and their approval, which includes 13 large mole-
cules (LM) and 28 small molecules (SM). Subclassifications 
of the LMs resulted in nine monoclonal antibodies (mAbs), 
two antibody drug conjugates (ADCs), one enzyme, and one 
fusion protein. Subclassifications of the SMs resulted in 16 
kinase inhibitors (KIs), eight non-KI small molecule-tar-
geted agents, three chemotherapeutic agents, and one radio-
active agent (Fig. 1, Table 1, Supplemental Table 1). 
Eleven of the 41 (26.8 %) NME approvals had dose 
optimization-related PMR/PMCs issued by the FDA, based 
on clinical reviews and E–R analysis results performed 
by sponsors and/or FDA reviewers (Table 1). Overall, the 
tendency to receive a PMR/PMC for dose optimization 
activities appears slightly higher for TKIs than other drug 
classes.
PMR/PMC dose optimization activities include requests 
for conducting additional clinical studies and/or E–R 
analyses for dose optimization/identification. Seven drugs 
received PMRs/PMCs to conduct clinical studies for evalu-
ation of whether an alternative to the proposed label dose 
would have a better benefit–risk profile. These included 
two evaluations of whether a higher dose would improve 
efficacy-1 mAb (ipilimumab) [9] and 1 radioactive agent 
(radium-223) [10] and five instances of whether a lower 
dose would provide a better safety profile without compro-
mising efficacy, including the small molecule KI and non-
KI agents (vandetanib, cabozantinib, ceritinib, lenvatinib, 
and panobinostat) [11–19]. Four other drug approvals 
resulted in PMRs/PMCs for additional E–R analysis results 
to support the proposed label dose, including one ADC 
(ado-trastuzumab emtansine) [20] and three KIs (ponatinib, 
regorafenib, and crizotinib) [21–24]. Further details on the 
label dose, correlation with MTD, E–R analysis results (in 
support of the label dose), and PMRs/PMCs for dose justi-
fication/optimization issued for these 41 drugs are provided 
in Table 1.
Fig. 1  Chronological order of 41 NMEs approved by the FDA to treat cancer indications during the survey period 2010 through the first quarter 
of 2015
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Table 1  Summary of label dose justification and post-marketing requirement/commitment for dose optimization of oncology drugs (n = 41) 
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An overview of pharmacometric methods for E–R anal-
ysis in NME applications is provided later in this review.
Approval outcomes of label dose related to MTD
Figure 2 illustrates outcomes for the 41 drugs surveyed, 
with or without a development strategy at the MTD. For 
26 of the 41 (63.4 %) NMEs, the MTD was identified dur-
ing dose escalation trials, and a MTD was not reached for 
the remaining 15 drugs. For the 26 drugs with an identi-
fied MTD, 21 (80.8 %) instances, the MTD was selected 
for the registration trials and also proposed by the spon-
sor as label dose, suggesting that the MTD dosing para-
digm dominates in oncology drug development. As shown 
in Fig. 2, for 21 of the 41 (51.2 %) NMEs, the MTD was 
proposed as the label dose and for the remaining 20 of the 
41 (48.8 %) NMEs, a dose lower than the MTD or maxi-
mum studied dose (MSD) was proposed as the label dose. 
Among the 21 drugs with the proposed MTD as the initial 
starting dose, this labeling was found to be justified follow-
ing FDA review in only 47.6 % (10 out of 21) instances, 
using criteria of no PMR/PMC for further dose optimiza-
tion or no upwards dose titration recommendations (Fig. 2, 
Table 1). These 10 drugs include a variety of therapeutic 
classes, including one mAb (dinutuximab), three chemo-
therapeutic drugs (cabazitaxel, eribulin, and pomalido-
mide), two KI (vemurafenib and palbociclib), three non-
KI targeted agents (omacetaxine mepesuccinate, olaparib, 
and belinostat) and one ADC (brentuximab vedotin). Two 
drugs (bosutinib and axitinib), where the approved label 
dose was the MTD, had an upward dose titration strategy to 
achieve dose levels above the MTD for individual patients 
meeting certain criteria, either recommended by the spon-
sor (axitinib) or FDA (bosutinib). Nine of 21 (42.9 %) of 
drugs developed at the MTD had dose optimization PMRs/
PMCs issued by the FDA. In five instances (vandetanib, 
cabozantinib, ceritinib, lenvatinib, and panobinostat) PMR 
clinical trials were requested to test a lower dose for safety 
concerns and in four instances (ponatinib, regorafenib, cri-
zotinib, and ado-trastuzumab emtansine) additional E–R 
data were to be provided for further label dose justification.
Among 20 drugs where the sponsor proposed a label 
dose lower than the MTD/MSD, five (25 %) had a MTD 
identified but proceeded with clinical development and 
registration trial using lower doses (afatinib, trametinib, 
enzalutamide, ramucirumab, and blinatumomab). In all five 
cases, the proposed label dose was justified and no dose 







1.4 mg/m2 IV 
D1 and 8, q3w
Yes No relationship 

















4 mg PO QD, 
21 day on, 7 
day off, q4w
Yes NA (insufficient 
PK data)
NA (insufficient PK 
data)
- -
ADC antibody drug conjugate, ADCC antibody-dependent cell-mediated cytotoxicity, ADCP antibody-dependent cellular phagocytosis, AEs 
adverse events, ALCL anaplastic large cell lymphoma, ALK anaplastic lymphoma kinase, ALL acute lymphoblastic leukemia, AP-CML accel-
erated phase chronic myelogenous leukemia, BCR-ABL break point cluster-Abelson tyrosine kinase fusion protein gene, BID twice per day, 
BP-Ph + CML blast phase Philadelphia chromosome-positive chronic myelogenous leukemia, BRAF a human gene that makes a protein called 
B-Raf, a member of the Raf kinase family, BSA body surface area, BTK Bruton’s tyrosine kinase, C1D1 cycle 1, day 1, CLL chronic lympho-
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17α-hydroxylase/C17,20-lyase; a key enzyme in the production of androgens in the testes and adrenal glands, eBC early breast cancer, ECD 
extracellular domain, EGFR epidermal growth factor receptor, E–R analyses exposure–response analyses, FL follicular B cell non-Hodgkin 
Lymphoma, FOLFIRI 5-fluorouracil, leucovorin, irinotecan, GM-CSF granulocyte–macrophage colony-stimulating factor, GSK GlaxoSmith-
Kline, HER2 human epidermal growth factor receptor 2, HHV-8 human herpesvirus-8, HIV human immunodeficiency virus, IL-2 interleukin-2, 
IBW ideal body weight, IV intravenous, MBC metastatic breast cancer, MCD multicentric Castleman’s disease, MCL mantle cell lymphoma, 
mCRC metastatic colorectal cancer, MCYR major cytogenetic response, MEK mitogen-activated extracellular signal regulated kinase, MMAE 
monomethyl auristatin E, MOA mechanism of action, MTC medullary thyroid cancer, MTD maximum tolerated dose, NA not assessed, NSCLC 
non-small cell lung cancer, ORR objective response rate, OS overall survival, PARP poly ADP ribose polymerase, PD-1 human programmed 
death receptor—1, PFS progression-free survival, PlGF placenta growth factor, PK pharmacokinetic(s), PMC postmarketing commitment, PMR 
postmarketing requirement, QTc corrected QT interval, q3w every-three-weeks, PO per os, QD one-a-day, QID 4 times per day, RA retinoic 
acid, RAF Raf kinase family, RCC renal cell carcinoma, RETR RET receptor tyrosine kinase, RTK receptor tyrosine kinases, SC subcutaneous 
injection, SCC squamous cell carcinoma, SLL small lymphocytic lymphoma, TKIs tyrosine kinase inhibitors, VEGF vascular endothelial growth 
factor, VEGFR vascular endothelial growth factor receptors
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trend of relationship. This may be inconclusive as most pivotal trials only test one dose level that did not result in a wide range of exposures. It is 
likely that a relationship exists but the lower exposures needed to reveal this relationship, were not studied in the analysis
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optimization postmarketing activities were issued (Fig. 2, 
Table 1). For the remaining 15 drugs where the MTD was 
not identified in early dose escalation trials, sponsors were 
able to successfully justify the dose used in the registration 
trial and the proposed label dose in 13 out of 15 (86.7 %) 
instances, typically by using exposure–efficacy/exposure–
safety (E–E/E–S) analysis. For the remaining two cases 
(ipilimumab and radium-223), PMRs were issued to test 
whether a higher dose would provide a greater degree of 
clinical benefit.
The mAbs are the largest category among large mole-
cules approved with nine approvals in the past 5 years. For 
six of these mAbs (ipilimumab, nivolumab, obinutuzumab, 
pembrolizumab, pertuzumab, and siltuximab), a MTD was 
not reached/identified during Phase 1 dose escalation stud-
ies, and a dose lower than the MSD was proposed as the 
label dose (Table 1). Of these, ipilimumab received a PMR 
to assess efficacy and safety for a higher dose (10 mg/kg), 
as compared to the approved label dose of 3 mg/kg [25, 
26]. For the remaining three mAbs (blinatumomab, dinu-
tuximab, and ramucirumab), the MTD was determined dur-
ing dose escalation. For dinutuximab, the MTD is proposed 
as the label dose; for blinatumomab and ramucirumab, the 
proposed label dose was lower than the MTD with none of 
the three drugs receiving dose optimization-related PMR/
PMCs. It is worth noting that blinatumomab is a novel type 
of mAb which is a bi-specific CD19-directed CD3 T cell 
engager.
Two ADCs were approved during the survey period, 
brentuximab vedotin and ado-trastuzumab emtansine [20, 
27]. In both cases, MTDs were determined in early clini-
cal trials and the MTD was selected for registration trials. 
For brentuximab vedotin, the FDA review concluded that 
the label dose balanced efficacy and safety well, and no 
PMR/PMC activities were suggested. For ado-trastuzumab 
emtansine, the FDA review suggested that higher drug 
concentration correlated with better efficacy measures, 
though there was no apparent concentration relationship 
to safety. It was concluded that there may be an opportu-
nity to improve clinical benefit by optimizing (increasing) 
the dose for low-exposure patients. A PMC analysis was 
implemented by the sponsor to further characterize the E–R 
relationship using data from a Phase 3 trial that was ongo-
ing during this review, to inform if a new dose optimization 
trial should be performed for a potential dose optimization 
clinical trial [20, 28–32].
Kinase inhibitors were the largest category within the 
SM classification (16 out of 28 SMs). During the survey 
period, 16 KIs were approved and accounted for 39.0 % 
of the 41 approvals. Figure 3 summarizes the dosing para-
digm for these 16 KIs and their drug approval outcomes. 
Thirteen of the 16 (81.3 %) KIs had their MTD identified 
during early clinical dose escalation trials (Fig. 3). Eleven 
of these 13 drugs (84.6 %) had the MTD proposed as the 
label dose for registration trials, again suggesting that the 
MTD dosing paradigm dominates for KIs. Upon review of 
the NDA, the FDA challenged the MTD as the label dose 
in most cases, with vemurafenib and palbociclib represent-
ing the only approvals of the MTD as the label dose [33] 
(Table 1). In the cases of bosutinib and axitinib, although 
Fig. 2  Summary of dosing paradigms for the 41 NMEs approved to treat cancer from 2010 through the first quarter of 2015
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the MTD was approved as the label dose, upward dose 
titration was approved. For bosutinib, dose titration was 
not used in the pivotal study; however, FDA recommended 
upward dose titration for bosutinib based on individual 
patient efficacy and tolerability, based on a retrospective 
analysis. For axitinib, upward dose titration was tested in 
the pivotal study based on individual patient safety/toler-
ability, and was approved by the FDA based on PK and 
exposure–response analysis [34, 35]. For the remaining 7 
KI drugs with approval of a label dose at the MTD, van-
detanib, cabozantinib, ceritinib, and lenvatinib received 
PMRs to conduct trials testing lower doses for safety con-
cerns [11–14] and 3 others received PMRs/PMCs to further 
assess E–R relationships using data in the ongoing Phase 
3 trial (ponatinib and crizotinib) [21, 23] or to submit a 
complete package of E–R assessment (regorafenib) [22] 
(Table 1). Among the 13 drugs with a MTD identified, the 
sponsors proposed registration trials at a lower dose than 
the MTD for two drugs (afatinib and trametinib) and both 
doses were approved with no postmarketing optimiza-
tion requirements [36, 37]. Out of 16 KIs that did not have 
an MTD identified and underwent development at a dose 
lower than the MSD, three drugs (ibrutinib, dabrafenib, and 
idelalisib) were approved by the FDA with no PMR/PMC 
dose optimization requirements being issued (Fig. 3 and 
Table 1) [28, 38, 39].
For eight non-KI small molecule-targeted drugs 
approved during the survey period, MTD was reached 
in five drugs and was proposed as the label dose in four 
of them, except for enzalutamide, for which a lower than 
MTD dose was used in the registration trial and approved 
as the label dose [15, 40–43] (Table 1). For these five 
drugs, four received approval of the proposed label dose 
without PMR/PMCs (belinostat, omacetaxine, olaparib, 
and enzalutamide). For panobinostat, a PMR was issued 
to conduct a randomized Phase 2 trial to characterize the 
safety and efficacy of at least two different doses and to 
conduct a Phase 3 trial of two doses for progression-free 
survival (PFS) assessment. For the three non-KI small 
molecule-targeted drugs (abiraterone acetate, carfil-
zomib, and vismodegib) [44–46] where MTDs were not 
reached during dose escalation trials, doses lower than 
the MSDs were proposed for study in the registration tri-
als and emerged as the label doses and no dose optimiza-
tion-related PMR/PMC was issued for these three drugs 
[44–46].
Three chemotherapeutic drugs (cabazitaxel, eribulin, 
and pomalidomide) used MTDs for study in the registration 
trials which were approved with no PMRs/PMCs related to 
dose optimization issued to the sponsors [47–49].
For the radioactive agent radium-223 dichloride injec-
tion, no MTD was determined in the Phase 1 dose escala-
tion trial and the label dose was proposed to be 50 kBq/kg. 
After review, FDA analysis suggested that patients with 
lower body weight (BW) had poorer overall survival (OS), 
while the incidence of Grade 3 or higher adverse events 
(AEs) was similar across a BW range. These findings 
resulted in a PMR issued [10] to conduct a randomized 
Phase 2 trial to evaluate the efficacy and safety of a dose 
higher than 50 kBq/kg [50].
Fig. 3  Summary of dosing paradigms for small molecule TKIs
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Overall, the survey data suggest that while the devel-
opment of oncology drugs at the MTD is still common 
(51.2 % of 41 cases and 80 % when the MTD is previously 
identified), success of the MTD as a justified label dose is 
infrequent, with nearly one-half of these NDA/BLA appli-
cations resulting in PMRs/PMCs issued for further dose 
optimization activities. PMR/PMC dose optimization activ-
ities occurred across all of the drug classes. The strategy 
for the development of novel KIs during the survey period 
appears to follow the historical MTD development para-
digm, with the majority entering clinical development with 
doses selected for registration trials and proposed label 
doses at the MTD (11 out of 16 KIs); however, despite their 
approval, only two out of 11 drugs had label doses equiva-
lent to the proposed MTD and seven out of 11 drugs had 
PMRs/PMCs issued for dose optimization efforts due to 
safety concerns. This suggests that the current dosing para-
digm for KIs needs to be shifted.
Upwards dose titration as a strategy of dose 
optimization
Most drugs have a specified downward dose titration 
method to manage AEs in their labels. Upward dose titra-
tion is an approach to individualize and potentially opti-
mize doses to reduce inter-subject PK variability, thus bal-
ancing efficacy and toxicity and increasing clinical benefit. 
Two (7.1 %) of the 28 approved NMEs (afatinib and axi-
tinib) tested an upward dose titration approach in their clin-
ical development with axitinib approved for this approach 
while afatinib not approved [34–36, 51]. FDA approved 
bosutinib label with upward dose titration recommenda-
tions, although this was not tested in the pivotal study.
For axitinib, the approved dosing strategy includes 
upward dose titration based on patient tolerability. The 
MTD established for axitinib in early clinical trials was 
5 mg twice daily without food. Analysis of three phase 2 tri-
als showed that a higher value for the area under the curve 
(AUC) was associated with longer PFS and OS and a higher 
overall response rate (ORR) in renal cell carcinoma [35, 
52]. However, greater exposure also correlated with a higher 
probability of toxicity, thus guiding the sponsor to imple-
ment a dose titration scheme in their Phase 2 and Phase 3 
registration trials. This dosing scheme comprised of a start-
ing dose of 5 mg twice daily, increased up to a maximum 
of 10 mg twice daily, based on tolerability. Retrospective 
analysis showed that there was considerable inter-subject 
variability in pharmacokinetics before dose titration and 
that patients who were able to tolerate axitinib upward 
dose titration had lower initial exposures. In these subjects, 
axitinib pharmacokinetics after dose titration appeared to 
match with those observed in subjects with no dose titration 
[35]. Clinical efficacy in patients with or without dose titra-
tion was further compared in a blinded Phase 2 trial; dose 
titration was found to improve the ORR [53]. Dose reduc-
tions to manage hypertension and proteinuria were also jus-
tified. Based on the above E–E and E–S analysis, as well 
as the positive registration study, which suggested an overall 
clinical benefit, the upward dose titration and dose reduction 
schemes were approved by the FDA [35]. The success of the 
axitinib dose titration strategy is facilitated by the ease of 
routine noninvasive assessment of the endpoints monitored 
for titration by the clinician and patient, e.g. blood pressure, 
fatigue, proteinuria, and diarrhea.
Afatinib is an example where the strategy of an upward 
dose titration did not result in clinical benefit. The regis-
tration trial used a dose of 40 mg, which was lower than 
the MTD of 50 mg, and was believed to be better tolerated. 
The design of the registration trial allowed for an upward 
dose escalation to 50 mg based on individual tolerability. 
E–R analysis of the trial indicated that patients in the high-
est exposure quartile had shorter PFS than those of other 
quartiles and that the higher exposure also increased the 
risk of AEs. Clinical observations also showed that 10 out 
of 16 patients (63 %) who were escalated to the 50 mg 
daily dose subsequently experienced dose reduction to 40 
or 30 mg. The results of the E–R analysis and the high per-
centage of dose modification led to the FDA recommenda-
tion for capping the daily dose of afatinib to a maximum of 
40 mg [36].
For bosutinib, a BCR-ABL kinase and Src-family KI 
indicated in CML, the registration trial was divided into 
two parts: Three doses were tested in Part I of the study, 
and the 500 mg dose with food was selected as the MTD 
for the Part II efficacy evaluation. While the bosutinib label 
dose is 500 mg [54], the FDA provided the following rec-
ommendation for upward dose titration; “consider dose 
escalation to 600 mg once daily with food in patients who 
do not reach complete hematological response by week 8 
or a complete cytogenetic response by week 12, who did 
not have Grade 3 or higher adverse reactions, and who are 
currently taking 500 mg daily.” The rationale for this state-
ment was not outlined in the “clinical pharmacology and 
biopharmaceutics reviews” for bosutinib [34], but presum-
ably is intended to maximize the potential for benefit in 
patients adequately tolerating bosutinib.
Biomarkers as a guide to dose selection/
justification
An exposure–biomarker relationship was provided by 
sponsors to justify the label doses for 5 NMEs: ibrutinib, 
trametinib, enzalutamide, abiraterone acetate, and carfil-
zomib [37, 38, 41, 44, 45] (Table 1).
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Ibrutinib, a drug targeting the Bruton’s tyrosine kinase 
(BTK) receptor, was approved to treat mantle cell lym-
phoma. No MTD for ibrutinib was established during dose 
escalation in early clinical trials, and a dose of 560 mg/day 
was proposed for the registration trial and approved as label 
dose. Dose selection of this drug was based on receptor 
occupancy, which had been shown to correlate with clinical 
efficacy. In the Phase 1 trial in which doses ranging from 
1.25 to 12.5 mg/kg were studied, a maximum BTK recep-
tor occupancy of >90 % and highest ORR was achieved 
at doses >2.5 mg/kg (>175 mg/day for 70 kg subject). 
The dose of 560 mg/day selected for the registration trial 
is therefore approximately threefold higher than the dose 
which provided a high degree of target binding, prevented 
lower exposure as a result of PK variability, demonstrated 
acceptable toxicity, and clinical activity in the early trial. 
FDA review summary documents note that a lower dose 
could be considered in future development; however, clini-
cal benefit was established at a 560 mg/day label dose and 
no PMR/PMCs were issued for dose optimization [38].
Trametinib is a drug which inhibits the MEK pathway 
and was developed to treat metastatic melanoma with a 
BRAF V600 mutation. While an MTD of 3 mg was deter-
mined in a dose escalation trial, development proceeded at 
a dose of 2 mg in Phase 2 and 3 trials [37]. Dose selec-
tion appeared to be based on the following rationale: 
(1) the long-term tolerability at the MTD of 3 mg was of 
concern with chronic treatment in the Phase 1 trial; there 
were fewer AEs at 2 mg versus 2.5 and 3 mg doses, (2) the 
mean concentration at the 2 mg once daily dose exceeded 
the preclinical target, (3) the response rate was similar at 
2 and 2.5 mg based on data from the Phase 1 trial, and (4) 
inhibition of pERK and Ki67, and enhancement of p27 in 
paired tumor biopsy specimens before and after treatment 
showed that trametinib at the 2 mg dose was more effective 
in modulating the biomarkers than at 0.5 and 1 mg [55]. 
In Phase 2 and registration trials, only the 2 mg dose was 
studied, and no clear E–R relationships were found. The 
FDA approved 2 mg as the label dose based on the multiple 
supportive factors listed above [37].
For enzalutamide, an androgen receptor inhibitor for 
treating castration-resistant prostate cancer, early clini-
cal trials established the MTD to be 240 mg/day, yet the 
160 mg/day dose was studied in the registration trial, which 
resulted in the approved label dose. The dose selection of 
160 mg was supported by the PSA response in the Phase 1 
trial.
Abiraterone acetate is an androgen biosynthesis inhibi-
tor that works by inhibiting the 17α-hydroxylase/C17,20-
lyase (CYP17) pathway and was developed to treat castra-
tion-resistant prostate cancer. When steroids upstream of 
the CYP17 pathway, (deoxycorticosterone and corticoster-
one), were used as biomarkers to assess the dose-dependent 
degree of target inhibition, a maximum effect appeared 
to be reached at a dose of 750 mg. Doses of 1000 and 
2000 mg did not raise the steroid biomarker levels further, 
thus suggesting 750 mg was close to the optimal biological 
dose, and given the acceptable safety profile, the 1000 mg 
dose was selected both for the registration trial and as the 
label dose [44].
The proteasome inhibitor carfilzomib is used to treat 
multiple myeloma with a recommended label Cycle 1 dose 
of 20 mg/m2/day, and if tolerated, increasing the doses for 
subsequent cycles to 27 mg/m2/day. During clinical devel-
opment, the Phase 1 trial assessed the inhibition of the 
chymotrypsin-like activity of the proteasome as a pharma-
codynamic marker after single and multiple doses. Dose-
dependent proteasome inhibition was observed in whole 
blood and peripheral blood mononuclear cells and appeared 
to plateau at doses of 11 mg/m2, which provided approxi-
mately 75 and 90 % proteasome inhibition following sin-
gle and multiple doses, respectively [45]. The rationale for 
the selected dose of 20/27 mg/m2 was primarily based on 
the safety and clinical best ORR of 50 % in the Phase 1 
dose escalation study and with the aim of providing a dose 
higher than the biologically active level of 11 mg/m2. The 
FDA approved the dose based on the overall clinical risk/
benefit observed in the Phase 2 registration study.
Summary of methods for E–R analysis applied 
in the evaluation of NME applications
This section categorizes and discusses the typical E–R 
analysis methods discussed in the “clinical pharmacology 
and biopharmaceutics reviews” for the oncology drugs 
approved during the survey period. E–R analysis may be 
further subcategorized into E–S and E–E analyses, which 
taken together provide an overall assessment for the “thera-
peutic index or therapeutic window” of the drug, and for 
“dose justification” or the need for “dose optimization” 
activities.
Exposure–response analyses of some type (E–E, E–S, or 
both) were performed in 36 (88 %) of the 41 applications 
by either the sponsor or the FDA or both (Table 1). Figure 4 
provides a summary of the E–R analysis methods for the 41 
drugs reviewed. FDA methods were chosen to report when 
different from sponsors. Methods from sponsors were 
also included if the FDA did not conduct the analysis but 
agreed with the interpretation of the E–R relationship by 
the sponsor. Multiple methods could thus be included for 
a given drug. If the same method (e.g., logistic regression) 
was used for multiple endpoints in E–S (or E–E) analy-
sis, it was only counted once. Only methods confirmed by 
FDA reviewers to be relevant to the clinical endpoints and 
dose justification were included, i.e. methods for certain 
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exploratory analyses were omitted for lack of correlation to 
clinical endpoints. In total, for the 41 drugs, there were 49 
E–S and 55 E–E analyses included.
E–E analysis
The aim of an E–E analysis is to assess the relationship 
between efficacy endpoints and PK exposure. The typical 
E–E analysis methods included are logistic regression and/
or regression modeling (19 instances) for ORR or other 
binary type data (e.g., major cytogenetic responses, major 
hematologic response, pathologic complete response); and 
Kaplan–Meier plots and Cox proportional hazard (Cox 
PH) model for survival data (26 instances). Box plots and 
longitudinal plots as exploratory assessments are also used 
but to a lesser extent (3 and 1 instances, respectively). 
For example, the longitudinal tumor size time profile was 
assessed by category of AUC for vemurafenib [33]. Similar 
to the application of logistic regression for the occurrence 
of AEs, multivariate logistic regression could be used to 
examine the impact of PK exposure and baseline prognos-
tic factors on the probability of binary efficacy endpoints. 
The Kaplan–Meier analyses of survival data stratified by 
PK exposure or dose is a qualitative way to explore the 
E–E relationship (Fig. 5a), as it does not account for the 
potential imbalances of risk factors between exposure or 
dose groups. There are only seven instances where Kaplan–
Meier plots alone were used to inform an E–E relationship. 
In the majority of instances, Kaplan–Meier plots and the 
Cox PH model were used together in the E–E analysis. The 
Cox PH model can incorporate the impact of prognostic 
factors, and this may provide an estimated effect of expo-
sure or dose on reducing the hazard rate, after adjusting 
for prognostic factors [25]. The Cox PH model assumed 
proportional hazard (time-constant hazard ratio, regard-
less of hazard rate fluctuations over time), given the linear 
relationship between natural logarithm of hazard function 
and the explanatory variables. Parametric time-to-event 
Fig. 4  Summary of analysis 
techniques for the 41 drugs 
reviewed. a E–S analysis, b 
E–E analysis
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analysis, which considered the underlying hazard func-
tion, was also implemented for survival data (one instance: 
palbociclib). As compared to the Cox PH model, the para-
metric model can define the baseline hazard function, allow 
flexible covariate relationship to the hazard function, and 
can consider the time-varying covariates to better identify 
potential prognostic factors and the effect of treatment [56].
E–S analysis
The aim of E–S analysis is to assess the tolerability (toxic-
ity/safety) risk associated with variation of exposure. The 
grading of an AE is usually defined with specific methods, 
such as the Common Terminology Criteria for Adverse 
Events scoring system [57]. In the E–S analysis, safety 
endpoints may be expressed as categorical outcomes (e.g., 
Grade 0, 1, 2, 3, and 4 AE), binary outcomes, such as “0” 
for “non-severe AE” (e.g., Grade 0–2) and “1” for “severe 
AE” (e.g., Grade 3 and above), or “0” for “no AE related 
dose modification” and “1” for “AE related dose modifi-
cation”, or continuous outcomes (e.g., neutrophil counts); 
exposure measures may include PK-related metrics (e.g., 
steady-state AUC, peak or trough concentration, either 
observed or population PK model predicted values), and 
dose-related metrics (e.g., dose intensity, BSA or BW, if 
BSA- or BW-based dosing), which can also be applied to 
E–E analysis. Graphical plots (e.g., box plot, logistic plot, 
and longitudinal plot) were the most common approaches 
for exploratory assessment of the E–S relationship. The 
box plot could be used to visually identify whether certain 
responses (categorical or binary endpoints) were associated 
with different exposures (representative plot is shown in 
Fig. 5b); however, these might fail to identify a relation-
ship that is not sufficiently steep [58]. The box plot may 
also be confounded by a potential lack of balance of prog-
nostic factors, since some patients may be predisposed to 
the safety risk because of their disease status. Thus, the box 
plot has not been widely used in the reviewed case exam-
ples (only in four instances).
Logistic plots and logistic regression models (Fig. 5c) 
are often used to explore and quantitate the E–S relation-
ship. Compared to the box plot, the logistic plot is more 
sensitive for detection of the E–S relationship [58]. How-
ever, like with the box plot, conclusions may be influenced 
by confounding factors. The multivariate logistic regression 
model can isolate the relationship between the exposure 
Fig. 5  Representative plots for a Kaplan–Meier plot, b box plot, c logistic plot and regression, and d longitudinal plots for efficacy or safety 
endpoints
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variable and binary outcomes from the impact of confound-
ing factors (i.e., demographic and prognostic factors). The 
probability of an AE at a given exposure or dose can be 
predicted thereafter by model simulation.
Logistic plots and regression models played a cen-
tral role in E–S analysis in several cases (29 instances). 
Another approach, although much less utilized for E–S 
analysis (5 instances), is the Kaplan–Meier plot stratifying 
by exposure, with the time-to-event endpoints including 
time to certain “severe AE” occurrence, or time to first dose 
modification due to AE. The Kaplan–Meier plot can pro-
vide important information relating to whether higher PK 
exposure will be associated with a “time-related” temporal 
occurrence of events (Fig. 5a), which cannot be provided 
by logistic regression. In a situation where safety endpoints 
are expressed as continuous outcomes, such as in two cases 
of neutrophil counts over time, for obinutuzumab and pal-
bociclib, the longitudinal plot (Fig. 5d) can be applied and 
stratified by obinutuzumab exposure groups to assess the 
impact on the endpoint time profile. As a more mechanistic 
approach, the longitudinal PK/PD model was implemented 
for palbociclib to evaluate the impact of dose and regimen 
on the neutrophil counts time profile.
Eight drugs did not have any E–S analysis, with seven 
out of eight having no or very limited PK. E–E analysis 
was able to be conducted for two out of those seven drugs 
(omacetaxine, mepesuccinate, and pertuzumab), using 
BSA or BW as the surrogate of exposure, which led to five 
instances of no E–E analysis conducted.
While E–R analyses are a common and critical element 
in dose evaluation in the SBA, we found that there were no 
instances where E–R analyses results were included in the 
product labeling for efficacy or safety endpoints. However, 
E–R language was common in the assessment of concen-
tration-QT (electrocardiogram) effect.
Some more advanced pharmacometric methods have 
also been explored for the E–R analysis and regimen selec-
tion based on literature reports and our own experiences. 
However, these methods were not used for any of the 41 
drugs reviewed here. These include, for example, longitudi-
nal and repeat time-to-event model for categorical data for 
E–S [59, 60], and the use of case match analysis in the E–E 
modeling of survival data [61]. These methodologies may 
be more robust to refine E–R relationships by integrating 
data in a longitudinal fashion and balancing prognostic fac-
tors; however, comparisons of these methodologies for E–R 
assessment in oncology need further evaluation.
Discussion and conclusion
Dose selection in oncology is complicated by a myriad 
of factors; several are exacerbated by the need to quickly 
deliver new effective therapies to cancer patients, who 
often have limited treatment options. Emerging concepts 
and strategies to determine the optimal dose in an era of 
molecularly targeted agents have been comprehensively 
reviewed by others [2, 3].
To extend the knowledge of dose selection and dose 
optimization during clinical drug development, we con-
ducted a comprehensive survey of the label dose for the 
41 NME applications for oncology drugs approved by the 
FDA from 2010 to the first quarter 2015. The public access 
to NME NDA/BLA applications and FDA reviews pro-
vided the ability to evaluate the strategies for dose selec-
tion of a drug during clinical development and the ability 
to identify the optimal dose. There were four key findings 
in our survey as follows: (1) Dose optimization-related 
PMRs/PMCs for NME applications are common and inde-
pendent of drug class with approximately 27 % of drugs 
approved having postmarketing activities issued related to 
dose justification/optimization, including clinical trials to 
study alternative doses to the label dose, or to conduct fur-
ther E–R analysis to justify the label dose. (2) Drug devel-
opment with doses at the MTD, when identified while still 
common did not lead to an optimal dose, with nine of 21 
(43 %) of drugs developed at the MTD having a PMR/PMC 
issued for dose optimization activities, which included five 
with trials to study a lower dose and four instances of addi-
tional E–R analyses. (3) Of 15 drugs where the MTD was 
not identified, the label dose was justified in 13 (87 %) with 
E–R analysis and two drugs having a PMR for trials at a 
higher dose. Thus, suggesting that the larger therapeutic 
window would allow studying if a higher dose would pro-
vide additional clinical benefit as suggested by E–E analy-
sis. (4) The majority of KIs had an identified MTD and of 
11 undergoing development at the MTD, four had PMR/
PMCs for trials at a lower dose for safety concerns, and 
three for additional E–R analyses in ongoing trials, sug-
gesting the relatively narrow therapeutic window of most 
KIs does not have an optimal/justified dose in majority of 
the cases when the MTD is used.
Of the drug approvals reviewed in our survey, two 
included upward dose titration during clinical development. 
Axitinib may be considered a prototypical example of suc-
cess for this approach, which utilized stepwise upward dose 
titration across three doses in individual patients showing 
decreased PK variability and improved efficacy on retro-
spective analysis. However, less favorable study outcomes 
were noted in the case of afatinib, where intra-patient dose 
escalation from a lower dose to the established MTD in the 
registration trial resulted in less efficacy and increased tox-
icity. Dose titration as a means of decreasing PK variability 
and enhancing clinical benefit merits more exploration in 
future clinical trials, particularly when high PK variability 
is observed.
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Currently, the application of blood biomarker data for 
dose selection is limited. Our survey indicates that overall, 
the use of biomarker data may be supportive in select cases 
for justification of the optimal dose in early clinical trials 
as well as for label dose justification, as illustrated by the 
recent drug approvals for enzalutamide and abiraterone for 
treating CRPC, ibrutinib for treating MCL and CLL, and 
carfilzomib approval for treating multiple myeloma.
The results of this survey show that E–E and/or E–S anal-
yses have been consistently and widely applied by sponsors 
and the FDA, (approximately 90 % of reviews) for assessing 
the appropriateness of the proposed dose. Generally, if there 
is a trend toward greater efficacy related to increased exposure 
without compromising safety, a PMR/PMC may be issued to 
evaluate a higher dose, with the aim of improving patient out-
comes. If there is both uncompromised efficacy and a trend 
toward improved safety profile with decreased exposure, a 
PMR/PMC may be issued to evaluate a lower dose.
In conclusion, the findings from our review support the 
need to develop clinical trial designs and data elements 
necessary to determine the optimal dose across all phases 
of drug development and also to fully assess the clinical 
potential of the NME [2–4]. There are multiple ongoing 
dose optimization PMR/PMC clinical trials and E–R analy-
ses [9–12], and the results of these studies will provide val-
uable information in support of future strategic directions 
in oncology drug development and dose optimization.
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